Invention Grant
- Patent Title: Eribulin-based antibody-drug conjugates and methods of use
-
Application No.: US15892921Application Date: 2018-02-09
-
Publication No.: US10322192B2Publication Date: 2019-06-18
- Inventor: Earl F. Albone , Xin Cheng , Daniel W. Custar , Keiji Furuuchi , Jing Li , Utpal Majumder , Toshimitsu Uenaka
- Applicant: Eisai R&D Management Co., Ltd.
- Applicant Address: JP Tokyo
- Assignee: Eisai R&D Management Co., Ltd.
- Current Assignee: Eisai R&D Management Co., Ltd.
- Current Assignee Address: JP Tokyo
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- Main IPC: A61K47/68
- IPC: A61K47/68 ; C07K16/28 ; C07K16/30 ; C07K16/32 ; A61K31/357

Abstract:
Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
Public/Granted literature
- US20180193478A1 ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE Public/Granted day:2018-07-12
Information query
IPC分类: